Is Most-Watched Stock Intuitive Surgical, Inc. (ISRG) Worth Betting on Now?

Intuitive Surgical (ISRG) has recently underperformed the broader market and its industry, returning -5.6% over the past month. Despite a strong track record of beating consensus EPS and revenue estimates in recent quarters and projecting robust future revenue growth (e.g., current quarter sales estimate of $2.41 billion, +18.2% YoY), minor negative revisions to earnings estimates and a premium valuation (Zacks Value Style Score D) have resulted in a Zacks Rank #4 (Sell), suggesting potential near-term underperformance.

Analysis

Intuitive Surgical (ISRG) presents a conflicting profile for investors, characterized by strong fundamental performance juxtaposed with near-term technical and sentiment headwinds. The company recently reported significant beats on both revenue and earnings, with revenue growing 21.4% year-over-year to $2.44 billion and EPS surprising by +14.06%. This growth is projected to continue, with consensus estimates pointing to a 17.1% revenue increase for the current fiscal year. However, the stock has underperformed, declining 5.6% over the past month against a 3.1% gain in the S&P 500. This weakness is attributed to minor, yet impactful, downward revisions in sell-side earnings estimates; the consensus for the current quarter and next fiscal year has decreased by 0.1% and 0.2%, respectively, over the last 30 days. These revisions, combined with a premium valuation reflected by a Zacks Value Style Score of 'D', have resulted in a Zacks Rank of #4 (Sell), suggesting a risk of near-term market underperformance despite the strong underlying business growth.

Key Decisions for Investors

• Investors should weigh the company's strong long-term revenue growth forecast, with estimates of +17.1% for the current year, against the near-term risk highlighted by the Zacks #4 (Sell) rating.
• Given the stock's recent -5.6% decline and premium valuation, traders should be cautious, as the negative earnings estimate revisions, though minor, are a key driver of the current bearish near-term outlook.
• Monitor future analyst earnings estimate revisions closely, as the article identifies this metric as the primary catalyst for near-term price movement and the rationale behind the current 'Sell' rating.
• Consider the consistent history of beating EPS estimates for four consecutive quarters as a sign of operational strength, but acknowledge that this has not been sufficient to prevent recent stock underperformance.